Velexbru (tirabrutinib hydrochloride) vs Brukinsa (zanubrutinib)

Velexbru (tirabrutinib hydrochloride) and Brukinsa (zanubrutinib) are both Bruton's tyrosine kinase (BTK) inhibitors used in the treatment of certain B-cell malignancies. Velexbru is known for its selective inhibition of BTK, potentially leading to fewer off-target effects, while Brukinsa has demonstrated a high response rate and a tolerable safety profile in clinical trials. When deciding between the two, it is important to consider individual patient factors such as specific indications, potential side effects, drug interactions, and the overall clinical evidence supporting each medication's efficacy and safety in the context of the patient's unique medical history and treatment goals.

Difference between Velexbru and Brukinsa

Metric	Velexbru (tirabrutinib hydrochloride)	Brukinsa (zanubrutinib)
Generic name	Tirabrutinib hydrochloride	Zanubrutinib
Indications	Approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL) and other B-cell malignancies in some regions	Approved for the treatment of mantle cell lymphoma (MCL) in patients who have received at least one prior therapy, Waldenström's macroglobulinemia, and marginal zone lymphoma
Mechanism of action	Bruton's tyrosine kinase (BTK) inhibitor	Bruton's tyrosine kinase (BTK) inhibitor
Brand names	Velexbru	Brukinsa
Administrative route	Oral	Oral
Side effects	Common side effects include neutropenia, thrombocytopenia, increased blood pressure, rash, and diarrhea	Common side effects include neutropenia, thrombocytopenia, upper respiratory tract infection, rash, and bruising
Contraindications	Known hypersensitivity to tirabrutinib or any of its excipients	Known hypersensitivity to zanubrutinib or any of its excipients
Drug class	BTK inhibitor	BTK inhibitor
Manufacturer	Ono Pharmaceutical Co., Ltd and BeiGene Ltd.	BeiGene Ltd.

Efficacy

Velexbru (Tirabrutinib Hydrochloride) Efficacy in Lymphoma

Velexbru, known by its generic name tirabrutinib hydrochloride, is a Bruton's tyrosine kinase (BTK) inhibitor used in the treatment of lymphoma. Its efficacy has been particularly noted in patients with mantle cell lymphoma (MCL) and other B-cell malignancies. Clinical trials have demonstrated that tirabrutinib can induce high response rates in relapsed or refractory MCL, which is a challenging condition to treat due to its aggressive nature. The drug's mechanism of action involves the inhibition of BTK, which is a critical component in the B-cell receptor signaling pathway that is essential for the survival and proliferation of malignant B-cells.

In studies, Velexbru has shown a favorable efficacy profile, with a significant proportion of patients achieving partial or complete responses. The overall response rate (ORR) and duration of response (DOR) have been used as primary measures of efficacy in clinical trials. While individual results vary, the data suggests that tirabrutinib is an effective treatment option for patients with B-cell lymphomas, especially for those who have limited treatment options due to relapsed or refractory disease.

Brukinsa (Zanubrutinib) Efficacy in Lymphoma

Brukinsa, with the active ingredient zanubrutinib, is another BTK inhibitor that has shown promise in the treatment of various types of lymphoma, including MCL and Waldenström's macroglobulinemia (WM). Zanubrutinib has been designed to be more selective than earlier BTK inhibitors, potentially leading to fewer off-target effects and improved safety profiles. In clinical trials, Brukinsa has demonstrated high ORRs in patients with relapsed or refractory MCL, suggesting that it is an effective therapeutic agent in this setting.

Furthermore, zanubrutinib has shown efficacy in the treatment of WM, which is a rare type of non-Hodgkin lymphoma. The ORR for patients treated with Brukinsa in clinical trials has been encouraging, and the treatment is associated with a durable response, which is critical for the management of chronic lymphoma conditions. The efficacy of Brukinsa in lymphoma makes it a valuable addition to the therapeutic arsenal against B-cell malignancies, providing new hope for patients who may not respond to traditional chemotherapy or other targeted therapies.

Regulatory Agency Approvals

Velexbru

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Brukinsa

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Velexbru or Brukinsa today

If Velexbru or Brukinsa are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Velexbru

Buy Brukinsa

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: